Sanofi India is planning to lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The volume-based agreement will discount the price of a three-month treatment course of Rifapentine by nearly 70 percent, from approximately $45 to $15 (ex works) in the public sectors of 100 low and middle-income countries burdened by TB and TB/HIV coinfection. Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world. The Indian government has set ambitious targets to eliminate TB by 2025.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
